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and implications for wider STI diagnosis and care:
a probability sample survey of the British population
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Nigel Field,1 Le Lu,1 Anne M Johnson,1 Jackie A Cassell3
ABSTRACT
Background Following widespread rollout of
chlamydia testing to non-specialist and community
settings in the UK, many individuals receive a chlamydia
test without being offered comprehensive STI and HIV
testing. We assess sexual behaviour among testers in
different settings with a view to understanding their
need for other STI diagnostic services.
Methods A probability sample survey of the British
population undertaken 2010–2012 (the third National
Survey of Sexual Attitudes and Lifestyles). We analysed
weighted data on chlamydia testing (past year),
including location of most recent test, and diagnoses
(past 5 years) from individuals aged 16–44 years
reporting at least one sexual partner in the past year
(4992 women, 3406 men).
Results Of the 26.8% (95% CI 25.4% to 28.2%) of
women and 16.7% (15.5% to 18.1%) of men reporting
a chlamydia test in the past year, 28.4% of women and
41.2% of men had tested in genitourinary medicine
(GUM), 41.1% and 20.7% of women and men
respectively tested in general practice (GP) and the
remainder tested in other non-GUM settings. Women
tested outside GUM were more likely to be older, in a
relationship and to live in rural areas. Individuals tested
outside GUM reported fewer risk behaviours;
nevertheless, 11.0% (8.6% to 14.1%) of women and
6.8% (3.9% to 11.6%) of men tested in GP and 13.2%
(10.2% to 16.8%) and 9.6% (6.5% to 13.8%) of
women and men tested in other non-GUM settings
reported ‘unsafe sex’, deﬁned as two or more partners
and no condom use with any partner in the past year.
Individuals treated for chlamydia outside GUM in the
past 5 years were less likely to report an HIV test in that
time frame (women: 54.5% (42.7% to 65.7%) vs
74.1% (65.9% to 80.9%) in GUM; men: 23.9%
(12.7% to 40.5%) vs 65.8% (56.2% to 74.3%)).
Conclusions Most chlamydia testing occurred in non-
GUM settings, among populations reporting fewer risk
behaviours. However, there is a need to provide
pathways to comprehensive STI care to the sizeable
minority at higher risk.
INTRODUCTION
Genital chlamydia infection is the most commonly
diagnosed STI in Britain, with >200 000 diagnoses
made in England in 2015,1 and an estimated popu-
lation prevalence of 1.5% in women and 1.1% in
men aged 16–44 years.2 Chlamydia is easily treated
with antibiotics; however, infection is usually
asymptomatic and therefore can often go undiag-
nosed and untreated, which may lead to serious
adverse sequelae including pelvic inﬂammatory
disease, ectopic pregnancy and tubal infertility.3
Since the early 2000s, chlamydia testing has been
expanded in all British countries in line with
national sexual health strategies with the aim of
increasing testing among those aged under 25 years
who are sexually active, the group most affected by
chlamydia.4–6 A National Chlamydia Screening
Programme (NCSP) was established in England in
2003, which recommends opportunistic screening
of men and women aged under 25 years annually
and on change of sexual partner in a range of
healthcare and non-healthcare settings.7 In
Scotland and Wales, testing of asymptomatic young
adults, particularly those at higher risk, is recom-
mended although there is no formal screening
programme.6 8 9
Partner notiﬁcation and testing for other STIs
including HIV are recommended for individuals
diagnosed with chlamydia regardless of the setting.
This may require referral to genitourinary medicine
(GUM), where the treatment service is unable to
provide these services.10–12 However, while GUM
services routinely undertake a sexual history and
assess risk of other STIs, this is not an established
standard of care for all those testing for chlamydia
in general practice (GP), where indeed many health
practitioners are not trained to make such an
assessment. Therefore, although the expansion of
chlamydia testing settings has the potential to reach
those who would not usually attend GUM services,
there could be a missed opportunity for diagnosis
of other STIs if high-risk individuals test in these
settings.
Prior to the NCSP, coverage of chlamydia testing
in England within GP was low, with women aged
≥25 years being disproportionately tested, and very
few tests carried out in men.13 14 Analysis from a
representative population survey—the second
National Survey of Sexual Attitudes and Lifestyles
(Natsal-2), undertaken in 1999–2001, before the
NCSP was introduced—found that those diagnosed
with chlamydia in GP reported lower risk beha-
viours than those diagnosed in GUM.15 More
recent NCSP and Natsal data show that positive
chlamydia tests are more common in GUM than
GP or other settings,1 16 suggesting that those
tested outside GUM are still lower risk; however,
up-to-date data on the demographic and
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behavioural characteristics of those testing in different settings
are needed. In this paper, we compare characteristics of those
aged 16–44 years tested for chlamydia in GUM, GP and other
settings using data from Natsal-3, a British probability sample
survey undertaken 2010–2012.
METHODS
Participants and procedures
Natsal-3 was a stratiﬁed probability sample survey of 15 162
men and women aged 16–74 years in Britain, interviewed in
2010–2012. The overall response rate was 57.7% (of all known
or estimated eligible addresses). Participants were interviewed
using a combination of computer-assisted face-to-face and self-
completion questionnaires. Non-response to individual ques-
tions (missing data) was low, typically 1–3%. Full details of the
methods used in Natsal-3 have been reported elsewhere.17 18
Here, we present results for 8397 participants (4992 women,
3405 men) aged 16–44 years with at least one sexual partner in
the past year, and further analysis of 2349 participants (1610
women, 739 men) who also reported being tested for chlamydia
in the past year.
Statistical analysis
All analyses were carried out using Stata V.13, (Stata Statistical
Software: Release 13. College Station, Texas, USA: StatCorp,
2013) accounting for stratiﬁcation, clustering and weighting of
the sample. Data were weighted to account for differential selec-
tion to the survey and to address non-response bias by age, sex
and region. We present demographic and behavioural character-
istics (percentages and 95% CIs) of those tested for CT in the
past year by most recent testing location: sexual health (GUM)
clinic, GP surgery (GP) or ‘other non-GUM settings’ (compris-
ing National Health Service (NHS) family planning clinic;
school, college or university; antenatal service; termination of
pregnancy clinic; private (non-NHS) clinic; hospital accident
and emergency; pharmacy; youth advisory clinic; internet and
other non-healthcare setting). We used multinomial regression
to calculate relative risk ratios (RRRs), comparing the demo-
graphic and behavioural characteristics of those tested in GP or
other locations with those tested in GUM. For each comparison
(eg, ‘other non-GUM settings’ vs GUM), the RRRs correspond
to the ORs ignoring the third location category (eg, GP). These
analyses were initially stratiﬁed by broad age group (16–24/25–
44 years) where numbers permitted but as the pattern of asso-
ciations was similar for both groups, ﬁnal analyses present
unadjusted data for all aged 16–44 years combined, with
age-adjusted RRRs (aRRRs) presented in the text where adjust-
ment affected associations. We report HIV testing among those
diagnosed with chlamydia, by location of chlamydia treatment,
with the time frame expanded to the past 5 years due to small
numbers diagnosed with chlamydia in the past year.
RESULTS
Of all participants aged 16–44 years with at least one sexual
partner in the past year, 26.8% (95% CI 25.4% to 28.2%) of
women and 16.7% (15.5% to 18.1%) of men reported a chla-
mydia test in the past year. Testing was more common in those
aged 16–24 years (55.4% (52.6% to 58.2%) of women, 36.0%
(33.2% to 38.9%) of men), the age group eligible for the NCSP
in England (table 1). Across all aged 16–44 years who had been
tested, 28.4% (25.8% to 31.9%) of women and 41.2% (37.5%
to 45.9%) of men had been tested in GUM, 41.1% (38.4% to
44.0%) and 20.7% (17.6% to 24.2%) of women and men
respectively had been tested in GP, and 30.5% (28.0% to
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33.1%) and 37.7% (33.6% to 41.9%) of women and men
respectively had been tested in other non-GUM settings includ-
ing NHS family planning clinic, antenatal service, termination
of pregnancy clinic, school, college, university—henceforth
referred to as ‘other non-GUM settings’. Internet-based testing
was rare, reported by only 0.6% (0.3% to 1.1%) of women and
1.9% (1.1% to 3.2%) of men tested for chlamydia in the past
year. Younger people were more likely to report internet-based
testing, reported as the location by 1.7% (1.0% to 2.6%) of
people aged 16–24 years compared with 0.4% (0.2% to 1.0%)
of people aged 25–34 years, and noone aged 35–44 years.
Women who most recently tested for chlamydia in GP were
more likely to be older, living with a partner, have no educa-
tional qualiﬁcations and living in rural areas than those tested in
GUM (table 2). The association with educational qualiﬁcations
became non-signiﬁcant after adjustment for age (aRRR=0.66
(95% CI 0.41 to 1.07); p=0.09). Women tested in other
non-GUM settings were more likely to be aged 25–34 years,
living with a partner, a student in full-time education and to live
in rural areas compared with those tested in GUM. There were
no demographic differences between men who had tested for
chlamydia in GP and those who tested at GUM clinics (table 3).
However, men tested for chlamydia in other non-GUM settings
were younger, less likely to be living with a partner and more
likely to be students compared with those tested in GUM; these
associations remained after adjustment for age (data not shown).
Compared with GUM, women tested in GP or other
non-GUM settings had lower numbers of sexual partners (past
year) and were less likely to report: same-sex partners (past
year), new partners from outside the UK and overlapping part-
nerships (both past 5 years) (table 4); these associations
remained after adjusting for age (data not shown). Similarly,
compared with men tested in GUM, those tested in GP or other
locations had lower partner numbers (past year) and were less
likely to report same-sex partners (past year), overlapping part-
nerships (past 5 years), unsafe sex (past year; GP only) or new
partners from outside the UK (past 5 years; other settings only)
(table 5); these associations remained after adjusting for age
(data not shown). Although those tested in GP or other settings
were generally less likely to report STI risk behaviours than
those tested in GUM, 11.0% (8.6% to 14.1%) of women tested
in GP and 13.2% (10.2% to 16.8%) of women tested in other
non-GUM settings reported ‘unsafe sex’, deﬁned as at least two
partners in the past year and no condom used with any partner
in the past year. The corresponding ﬁgures for men were 6.8%
(3.9% to 11.6%) of those tested in GP and 9.6% (6.5% to
13.8%) of those tested in other settings. Of the women report-
ing unsafe sex, 85.1% (75.7% to 91.2%) of those tested in GP
Table 2 Demographic characteristics of those tested for chlamydia in the past year, by location of test—women
Characteristics of women reporting a chlamydia test in the
past year Multinomial regression analysis
Tested in sexual
health (GUM)
clinic Tested in GP
Tested in other
settings
Tested in GP vs
GUM
Tested in other
settings vs GUM
% 95% CI % 95% CI % 95% CI RRR 95% CI) RRR 95% CI
Women
Age (years)
16–24 56.8 50.7 –62.6 47.1 42.8–51.5 65.2 60.2–70.0 1.00 – 1.00 –
25–34 34.0 28.6–39.8 35.5 31.5–39.7 24.6 20.8–28.9 1.26 0.93–1.71 0.63 0.45–0.89
35–44 9.2 6.1–13.8 17.4 13.6–21.9 10.1 6.9–14.7 2.27 1.32–3.92 0.96 0.50–1.83
Country of residence
England 90.5 87.1–93.1 87.0 83.8–89.6 92.5 90.0–94.4 1.00 1.00
Scotland 5.3 3.3–8.3 8.3 6.2–11.1 4.4 2.9–6.7 1.63 0.89–2.98 0.81 0.43–1.53
Wales 4.2 2.7–6.4 4.7 3.2–6.8 3.1 2.1–4.6 1.17 0.63–2.18 0.73 0.41–1.28
Relationship status
Live with a partner (including married) 28.4 23.4–34.1 46.3 41.9– 50.8 37.9 32.9–43.1 1.00 – 1.00 –
In a steady ongoing relationship 31.3 26.4–36.6 29.8 25.9–34.0 33.8 29.4–38.5 0.58 0.41–0.84 0.81 0.55–1.20
Not in a steady relationship 40.3 34.9–46.0 23.9 20.5–27.8 28.3 24.0–33.0 0.36 0.25–0.53 0.53 0.36 –0.77
Education level*
No academic qualifications 7.5 5.2–10.6 11.4 8.8–14.6 7.1 4.9–10.2 1.00 – 1.00 –
Academic qualifications typically gained at age 16 28.8 23.8–34.3 33.7 29.6–38.0 27.6 23.4–32.2 0.83 0.49– 1.40 1.00 0.55–1.83
Studying for/attained further academic qualifications 63.7 58.1–69.1 54.9 50.5–59.3 65.3 60.4–69.9 0.61 0.38–0.98 1.07 0.61–1.88)
Student in full-time education
No 79.40 73.8–84.1 83.3 79.8–86.2 70.3 65.5–74.6 1.00 – 1.00 –
Yes 20.6 15.9–26.2 16.7 13.8–20.2 29.7 25.4–34.5 0.78 0.53–1.14 1.63 1.12–2.39
Area of residence
Urban 89.7 86.5–92.2 83.9 80.1–87.0 84.1 80.0–87.5 1.00 – 1.00 –
Rural 10.3 7.8–13.5 16.1 13.0–19.9 15.9 12.5–20.0 1.68 1.14–2.47 1.65 1.10–2.46
Denominator (unwt, wt)† 457, 265 650, 384 503, 284
Denominator is those aged 16–44 years reporting at least one partner in the past year.
*Participants coded as per their highest academic attainment. Excludes those aged <17 years or with foreign qualifications.
†Denominator is smaller for some analyses due to missing data: 3 women had missing data for relationship status; 60 women had missing education level.
GP, general practice; GUM, genitourinary medicine; RRR, unadjusted relative risk ratio for testing in GP/other settings, compared with testing in GUM; unwt, unweighted denominator;
wt, weighted denominator.
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and 73.1% (59.8% to 83.2%) of those tested in other settings
had not attended a GUM clinic in the past year. Among men,
79.8% (64.6% to 89.5%) of those reporting unsafe sex who
were tested for chlamydia in GP or other non-GUM settings
(combined due to small numbers) had not attended a GUM
clinic in the past year.
A small proportion of men who tested for chlamydia in GP
or other non-GUM settings reported sex with another man in
Table 4 Behavioural characteristics of those tested for chlamydia in the past year, by location of test—women
Characteristics of women reporting a chlamydia test in the past
year Multinomial regression analysis
Tested in sexual
health (GUM)
clinic Tested in GP
Tested in other
settings
Tested in GP
vs GUM
Tested in other
settings
vs GUM
% 95% CI % 95% CI % 95% CI RRR 95% CI RRR 95% CI
Women
Number of partners*, past year
1 46.9 41.2–52.7 72.0 67.9–75.8 63.2 58.1–68.0 1.00 – 1.00 –
2 19.0 15.0–23.7 11.4 8.8–14.6 16.4 13.2–20.3 0.39 0.26–0.59 0.64 0.43–0.97
3+ 34.1 28.7–39.9 16.6 13.6–20.1 20.3 16.8–24.5 0.32 0.22–0.45 0.44 0.31–0.64
Same-sex partner(s), past year 8.9 6.3–12.5 2.7 1.6–4.3 3.9 2.4–6.2 0.28 0.15–0.53 0.42 0.22–0.77
Unsafe sex†, past year 14.7 11.4–18.7 11.0 8.6–14.1 13.2 10.2–16.8 0.72 0.48–1.08 0.88 0.59–1.32
Concurrency in past year‡ 22.3 17.9–27.4 8.5 6.5–10.9 14.9 11.6–19.0 0.32 0.22–0.48 0.61 0.41–0.91
New partners from outside UK§, past five years 17.5 13.4–22.6 8.6 6.5–11.3 10.1 7.5–13.5 0.44 0.29–0.68 0.53 0.34–0.83
A sexual partner was concurrent, past five years
(yes/probably)
61.5 55.7–67.0 51.1 46.5–55.8 49.1 44.0–54.2 0.65 0.48–0.88 0.60 0.44–0.83
Denominator (unwt, wt)¶ 457, 265 650, 384 503, 284
*Opposite and/or same-sex partners.
†Defined as two or more partners in the past year and not used a condom in the past year.
‡Overlap between any of three most recent partners in the past year.
§Includes partners acquired when abroad and when in the UK.
¶Denominator is smaller for some analyses due to missing data: 10 women had missing data for number of partners, 1 for same-sex partners, 6 for unsafe sex, 139 for concurrency and
51 for partners’ concurrency.
GP, general practice; GUM, genitourinary medicine; RRR, unadjusted relative risk ratio for testing in GP/other settings, compared with testing in GUM; unwt, unweighted denominator;
wt, weighted denominator.
Table 5 Behavioural characteristics of those tested for chlamydia in the past year, by location of test—men
Characteristics of men reporting a chlamydia test in the past
year Multinomial regression analysis
Tested in sexual
health (GUM)
clinic Tested in GP
Tested in other
settings
Tested in GP
vs GUM
Tested in other
settings
vs GUM
% 95% CI % 95% CI % 95% CI RRR 95% CI RRR 95% CI
Men
Number of partners*, past year
1 40.1 33.9–46.6 54.1 45.1–62.9 49.8 42.9–56.7 1.00 – 1.00 –
2 18.2 13.5–24.1 11.5 7.2–18.0 25.1 19.4–31.9 0.47 0.24–0.92 1.11 0.66–1.87
3+ 41.7 35.3–48.4 34.3 26.5–43.2 25.1 20.1–30.8 0.61 0.38–0.99 0.48 0.32–0.74
Same-sex partner(s), past year 11.6 8.1–16.3 2.3 0.8–6.5 3.2 1.8–5.6 0.18 0.06–0.57 0.25 0.12–0.51
Unsafe sex†, past year 14.0 10.3–18.6 6.8 3.9–11.6 9.6 6.5–13.8 0.45 0.23–0.89 0.65 0.38–1.12
Concurrency in past year‡ 29.4 23.1–36.6 18.2 12.3–25.9 19.4 13.8–26.7 0.53 0.30–0.93 0.58 0.34–0.98
New partners from outside UK§, past 5 years 27.3 21.7–33.7 22.1 15.7–30.3 13.8 9.9–18.8 0.76 0.45–1.28 0.43 0.26–0.69
A sexual partner was concurrent, past 5 years
(yes/probably)
61.9 55.3–68.0 58.8 49.4–67.6 45.6 38.7–52.7 0.88 0.56–1.40 0.52 0.35–0.76
Denominator (unwt, wt)¶ 295, 243 151, 121 293, 220
Denominator is those aged 16–44 years reporting at least one partner in the past year.
*Opposite and/or same-sex partners.
†Defined as two or more partners in the past year and not used a condom in the past year.
‡Overlap between any of three most recent partners in the past year.
§Includes partners acquired when abroad and when in the UK.
¶Denominator is smaller for some analyses due to missing data: 3 men had missing data for number of partners, 4 for unsafe sex, 60 for concurrency and 24 for partners’ concurrency.
GP, general practice; GUM, genitourinary medicine; RRR, unadjusted relative risk ratio for testing in GP/other settings, compared with testing in GUM; unwt, unweighted denominator;
wt, weighted denominator.
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the past 5 years (2.3% (0.8% to 6.5%) in GP, 3.2% (1.8% to
5.6%) in other settings). The small numbers prohibit further
detailed analysis of this group; however, of the 21 men who
have sex with men (MSM) tested for chlamydia in GP/other set-
tings in the past year, only 4 reported an HIV test while 4
reported attending a sexual health clinic in the same time frame.
A more detailed breakdown of the demographic and behav-
ioural proﬁles by non-GP and non-GUM testing locations can
be found in online supplementary appendix tables 1 and 2.
Women tested in antenatal services were generally older, living
with a partner and reported one partner in the past year.
However, approximately 1 in 20 of these women reported
unsafe sex or concurrency in the past year, and 2 in 5 thought a
partner had been concurrent in the past 5 years.
Of all participants with at least one sexual partner in the past
year, 4.3% (3.7% to 4.9%) (n=285) women and 4.2% (3.5%
to 5.0%) (n=178) men reported a diagnosis of chlamydia in the
past 5 years. Of these, 58.1% (51.0% to 64.6%) of women and
76.7% (68.7% to 83.2%) of men were (most recently) treated
in GUM, 26.5% (20.8% to 33.1%) and 18.4% (12.6% to
26.1%) of women and men respectively were treated in GP and
15.4% (10.9% to 21.4%) and 4.9% (2.3% to 10.2%) were
treated elsewhere. Overall, 66.1% (59.1% to 72.4%) of women
and 56.0% (47.0% to 64.6%) of men treated for chlamydia in
the past 5 years reported an HIV test in the same time frame.
HIV testing was less common among those treated for chla-
mydia in GP/other locations (combined due to small numbers)
compared with those treated in GUM: 54.5% (42.7% to
65.7%) vs 74.1% (65.9% to 80.8%) for women (p=0.005),
23.9% (12.7% to 40.5%) vs 65.8% (56.2% to 74.3%) for men
(p<0.0001). Among women tested for chlamydia in GP/other
settings, around half had tested for HIV as part of a sexual
health check and 29% due to pregnancy (see online supplemen-
tary appendix table 3). Very few women treated for chlamydia
in the past year had tested for HIV due to being advised to do
so by a doctor (2.9% of those treated in GUM, 1.0% of those
treated in GP/other settings).
DISCUSSION
The majority of those aged 16–44 years who reported recent
testing for chlamydia were tested outside GUM, particularly
among women, of whom 41.1% tested in GP and 30.5% tested
in other non-GUM settings. Women who were tested in GP or
other non-GUM settings were more likely to be older, in a rela-
tionship and to live in rural areas than those tested in GUM.
Women and men tested in GP or other non-GUM settings gen-
erally reported lower traditionally ascribed STI ‘risk behaviours’,
including in terms of partner numbers, same-sex partners and
overlapping partnerships. However, a sizeable minority of those
tested outside GUM did report risk behaviours, including unsafe
sex (deﬁned as two or more partners and no condoms used
with any partner in the past year), which was reported by
11.0% and 13.2% of women tested in GP and other non-GUM
settings, and 6.8% and 9.6% of men tested in GP and other
non-GUM settings, respectively. The majority of these indivi-
duals had not attended GUM in the same time frame. A minor-
ity (approximately 3%) of men who had been tested for
chlamydia outside GUM reported same-sex partners in the past
5 years, and most of these individuals had not been tested for
HIV or attended a GUM clinic in the past year. Despite recom-
mendations that those diagnosed with chlamydia should be
tested for other STIs including HIV,10 12 the majority of those
treated for chlamydia outside GUM in the past 5 years did not
report an HIV test in the same time frame.
Our data conﬁrm, at population level, the increase in chla-
mydia testing in GP and other non-GUM settings reported from
NCSP and elsewhere, from a low base in the early 2000s when
few men were tested or diagnosed outside GUM and a high pro-
portion of women tested were over the age of 25.14 19 20 The
ﬁnding that a substantial proportion of chlamydia tests are now
carried out in GP and other non-GUM settings is in line with
routine data collected for people aged15–24 years by the NCSP
in England, with around half of these tests occurring in
non-GUM settings in 2015,1 and routine GP data showing
increases in diagnosis rates in GP settings from 22.8 per
100 000 population in 2000 to 29.3 per 100 000 in 2011.21
Our data show that around half of those tested in GP and three-
ﬁfths of those tested in other non-GUM settings were within
the NCSP target age range (under 25 years). Individuals tested
in GP and in other non-GUM settings across the 16–44 age
range reported lower risk behaviours than those tested in GUM,
which is consistent with data from the NCSP.1 However, this
does not necessarily imply inappropriate testing, for example,
previous analyses of Natsal-3 have shown that a substantial
amount of chlamydia infections in women aged 16–44 years
were among those with only one partner in the past year,2 and
testing those aged 16–24 years was generally higher among
those at greater risk.16 Natsal ﬁndings on the use of the internet
for sexual health have been discussed in more detail else-
where.22 We found lower levels of internet-based testing than
the English NCSP data for a similar period.23 Furthermore,
provision of eSexual Health has increased in recent years there-
fore the ﬁndings presented here are likely to underestimate the
current role of internet testing. The ﬁnding of lower rates of
HIV testing among those treated for chlamydia in non-GUM
settings is in line with data suggesting low HIV testing generally,
and among patients diagnosed with chlamydia, in GP.24 25 Our
data conﬁrm from the service user side that MSM and others
with more complex STI-related needs are incompletely served in
community settings.26
The wider strengths and limitations of Natsal-3 have been
reported elsewhere.17 Strengths include the use of probability sam-
pling methods to obtain a sample broadly representative of the
general population in Britain, and the coverage of all three coun-
tries in Britain, alongside detailed behavioural data that are not
routinely collected in surveillance of testing. As with all surveys,
there was non-response to the interview (response rate 58%);
however, the sample was weighted to the age, sex and regional
proﬁle of the British population, and after this weighting had been
applied the sample was generally comparable to the British popu-
lation on other demographic characteristics.17 Our study relies on
self-reported data, which may be subject to recall and reporting
biases. We only collected data on location of the most recent chla-
mydia test so our data may not represent all recent testing if parti-
cipants tested more than once, although there is evidence that
retesting rates were low during the study period.27 28 Sample size
limited our ability to explore testing location by ethnicity or to
look at regional differences, and we cannot therefore comment on
the relationship between testing venue and known inequalities in
STI incidence,29 which may be particularly relevant to HIV testing
given the known missed opportunities for diagnosis.30 We do not
know the time sequences of events; therefore, it is possible that
HIV testing was unrelated to the chlamydia diagnosis. Given this
was a population survey, the number of individuals recently diag-
nosed with chlamydia was small; therefore, the number treated
with chlamydia in GP or other non-GUM settings was insufﬁcient
for a detailed analysis even when we expanded the time frame to
the past 5 years.
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GP and other non-GUM settings make a growing contribution
to chlamydia testing. By including behavioural factors in a
population-based sample and comparing risk characteristics
between settings, our data can inform the planning and target-
ing of sexual health services. Individuals testing in GP and other
non-GUM settings have on average lower rates of STI risk beha-
viours and are consequently likely to be at lower risk of other
STIs including HIV; therefore, the risk of missed opportunities
to diagnose other STIs in these groups is unlikely to outweigh
the beneﬁts of greater availability of chlamydia testing.
However, a sizeable minority of those tested in non-GUM set-
tings reported recent risk behaviours, indicating potential
STI-testing needs beyond chlamydia testing; therefore, it is
essential that these settings both ensure appropriate care path-
ways are available for such individuals and ensure individuals
become aware of their additional testing and prevention needs.
These may include HIV and other STI testing, and in some cases
prophylaxis such as human papillomavirus and hepatitis B vac-
cination and HIV pre-exposure prophylaxis for higher-risk indi-
viduals. HIV testing was used as an indicator of whether
patients diagnosed with chlamydia received appropriate wider
STI care following this diagnosis, as recommended in national
guidelines, including speciﬁc guidelines for the management of
STIs in GP.10 12 Although it is concerning that a lower propor-
tion of those treated for chlamydia in the past 5 years in GP and
other non-GUM settings reported an HIV test in that time
frame, we do not know whether the participants were offered
and declined a test, nor whether they were offered or received
tests for other STIs or partner notiﬁcation. Population-based
probability samples have an important role to play in under-
standing the population proﬁles accessing different STI services
and continue to make a contribution to the efﬁcient and clinic-
ally effective planning of comprehensive sexual health services,
of which chlamydia testing is only a part.
Key messages
▸ The majority of chlamydia testing in Britain now occurs
outside of genitourinary medicine (GUM), with those tested
in general practice and other non-GUM settings less likely to
report traditionally ascribed risk behaviours.
▸ However, a sizeable minority of those testing outside of
GUM report higher-risk behaviours, of whom most have not
attended GUM.
▸ Despite national recommendations that those diagnosed
with chlamydia should be tested for other STIs including
HIV, most individuals treated for chlamydia outside of GUM
did not report an HIV test in the same time frame.
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